The US revenues for the first quarter 2011 were $33.9m, an increase of 19.1% from the $28.4m in the prior year period.
International revenues were $15.9m, more than double from the $6.9m reported in the first quarter 2010.
Gross profit was $32m, an increase of $8.4m over the first quarter 2010 of $23.6m.
During the period the company has received 510(k) clearance for the Solus ALIF System, a zero-profile, single-action locking implant that is used in anterior lumbar interbody fusion (ALIF) procedures, from the US Food and Drug Administration.
Patrick Ryan, Abbott Vascular Devices Vice President-North Asia, was named as chief operating officer.
Alphatec president and chief executive officer Dirk Kuyper said in the US, they have re-established revenue momentum and continue to achieve growth rates that exceed the US spine market.
"We achieved record revenues in Japan and strong growth in Asia Pacific and Latin America," Kuyper said.
"We have successfully positioned Alphatec Spine as a global leader within the spine market, and we continue to be laser-focused on driving our differentiated technologies in Aging Spine, MIS and Biologics to gain market share globally. We are particularly pleased with the rapid product uptake of PureGen, and the 510(k) clearance of Solus during the quarter."
